SAGE THERAPEUTIC
NASDAQ: SAGE (Sage Therapeutics, Inc.)
Kemas kini terakhir: 6 jam lalu6.52
0.04 (0.62%)
Penutupan Terdahulu | 6.48 |
Buka | 6.50 |
Jumlah Dagangan | 595,283 |
Purata Dagangan (3B) | 1,102,570 |
Modal Pasaran | 408,286,976 |
Harga / Jualan (P/S) | 8.53 |
Harga / Buku (P/B) | 1.01 |
Julat 52 Minggu | |
Tarikh Pendapatan | 29 Jul 2025 - 4 Aug 2025 |
Margin Operasi (TTM) | -476.01% |
EPS Cair (TTM) | -5.80 |
Pertumbuhan Hasil Suku Tahunan (YOY) | 78.00% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 2.89% |
Nisbah Semasa (MRQ) | 9.13 |
Aliran Tunai Operasi (OCF TTM) | -311.09 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | -179.04 M |
Pulangan Atas Aset (ROA TTM) | -36.35% |
Pulangan Atas Ekuiti (ROE TTM) | -63.53% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Biotechnology (US) | Menurun | Menurun |
Biotechnology (Global) | Menurun | Menurun | |
Stok | Sage Therapeutics, Inc. | Menaik | Menurun |
AISkor Stockmoo
Konsensus Penganalisis | 2.0 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | -2.0 |
Purata Bergerak Teknikal | -1.5 |
Osilator Teknikal | -2.5 |
Purata | -1.00 |
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others. |
|
Sektor | Healthcare |
Industri | Biotechnology |
Gaya Pelaburan | Small Value |
% Dimiliki oleh Orang Dalam | 10.41% |
% Dimiliki oleh Institusi | 84.54% |
Pemilikan
Nama | Tarikh | Syer Dipegang |
---|---|---|
Caligan Partners Lp | 31 Mar 2025 | 3,052,538 |
Tig Advisors, Llc | 31 Mar 2025 | 2,732,271 |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
29 Apr 2025 | Pengumuman | Sage Therapeutics Announces First Quarter 2025 Financial Results and Highlights Pipeline and Business Updates |
15 Apr 2025 | Pengumuman | Sage Therapeutics to Report First Quarter 2025 Financial Results on Tuesday, April 29, 2025 |
04 Mar 2025 | Pengumuman | Sage Therapeutics Announces R&D Leadership Transition |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2025 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |